» Articles » PMID: 35990714

Diagnosis and Treatment of Hepatitis C Virus Infection: a Tool for Engagement with People Who Inject Drugs in Vancouver's Downtown Eastside

Overview
Journal Can Liver J
Specialty Gastroenterology
Date 2022 Aug 22
PMID 35990714
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Vancouver's Downtown Eastside (DTES) faces the interrelated challenges of poverty, homelessness, mental health, addiction, and medical issues such as hepatitis C virus (HCV). This study evaluates a new model of engagement with people who inject drugs (PWID) in the DTES.

Methods: Our centre has developed the community pop-up clinic (CPC) to engage vulnerable populations such as PWID. Rapid HCV testing is offered using the OraQuick saliva assay. If a test is positive, immediate medical consultation and an incentivized clinic appointment are offered. At this appointment, an HCV treatment plan is developed, along with a plan for engagement in multidisciplinary care.

Results: In 12 months, 1,283 OraQuick tests were performed at 44 CPCs; 21% of individuals were found to be positive for HCV (68% of whom were PWID). Of individuals positive for HCV antibodies who consulted with the on-site doctor, 50% engaged in care in our clinic-61% of whom have initiated interferon-free directly acting antiviral (DAA) HCV therapy with 100% cured of HCV (per protocol). Individuals who did not engage in care were significantly more likely to be homeless ( < .0001).

Conclusion: CPCs paired with a multidisciplinary model of care address the needs of vulnerable populations such as PWID, particularly in the management of HCV with interferon-free DAA therapies.

Citing Articles

Understanding Barriers to Hepatitis C Antiviral Treatment in Low-Middle-Income Countries.

Venkatesh R, Huang A, Gurmessa K, Hsu E Healthcare (Basel). 2025; 13(1.

PMID: 39791650 PMC: 11720484. DOI: 10.3390/healthcare13010043.


Optimizing Hepatitis C Treatment Monitoring: Is Sustained Virologic Response at 4 Weeks Becoming the New Standard?.

Milosevic I, Filipovic A, Beronja B, Mitrovic N, Ruzic M, Simic J Microorganisms. 2024; 12(10).

PMID: 39458359 PMC: 11509943. DOI: 10.3390/microorganisms12102050.


A comparison of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for the treatment of hepatitis C infection among people who inject drugs.

Yi S, Truong D, Conway B J Virus Erad. 2024; 10(3):100388.

PMID: 39319041 PMC: 11420441. DOI: 10.1016/j.jve.2024.100388.


Evaluation of a Project Integrating Financial Incentives into a Hepatitis C Testing and Treatment Model of Care at a Sexual Health Service in Cairns, Australia, 2020-2021.

Dawe J, Gorton C, Lewis R, Richmond J, Wilkinson A, Pedrana A Viruses. 2024; 16(5).

PMID: 38793681 PMC: 11125761. DOI: 10.3390/v16050800.


'': Barriers to pharmacy-based identification and treatment of hepatitis C in Victoria, Canada.

Selfridge M, Barnett T, Lundgren K, Guarasci K, Drost A, Fraser C Can Liver J. 2024; 7(2):257-272.

PMID: 38746863 PMC: 11089472. DOI: 10.3138/canlivj-2023-0016.


References
1.
Hirsch K, Wright T . "Silent killer" or benign disease? The dilemma of hepatitis C virus outcomes. Hepatology. 2000; 31(2):536-7. DOI: 10.1002/hep.510310241. View

2.
Cha Y, Park Q, Kang E, Yoo B, Park K, Kim J . Performance evaluation of the OraQuick hepatitis C virus rapid antibody test. Ann Lab Med. 2013; 33(3):184-9. PMC: 3646192. DOI: 10.3343/alm.2013.33.3.184. View

3.
Trubnikov M, Yan P, Archibald C . Estimated prevalence of Hepatitis C Virus infection in Canada, 2011. Can Commun Dis Rep. 2018; 40(19):429-436. PMC: 5864479. DOI: 10.14745/ccdr.v40i19a02. View

4.
Simmons B, Saleem J, Hill A, Riley R, Cooke G . Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin Infect Dis. 2016; 62(6):683-694. PMC: 4772843. DOI: 10.1093/cid/civ948. View

5.
Cachay E, Hill L, Wyles D, Colwell B, Ballard C, Torriani F . The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care. PLoS One. 2014; 9(7):e102883. PMC: 4103859. DOI: 10.1371/journal.pone.0102883. View